|Day's Range||24.60 - 24.60|
Inogen (INGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
(Reuters) -U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said.
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $547.34, marking a -1.75% move from the previous day.